Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Cameron

Showing results (401-410 of 481) with videos related to

Pageof 49
Sort By:
The New England Journal of Medicine|December 29, 2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancerCharles E Geyer, John Forster, Deborah Lindquist, et al.
Nucleic Acids Research|January 12, 2020
Artificial escape from XCI by DNA methylation editing of the CDKL5 geneJulian A N M Halmai, Peter Deng, Casiana E Gonzalez, et al.
Nutrition (Burbank, Los Angeles County, Calif.)|April 30, 2021
Responsiveness of one-carbon metabolites to a high-protein diet in older men: Results from a 10-wk randomized controlled trialNicola A Gillies, Amber M Milan, Pamela H P Chia, et al.
Nature Medicine|January 6, 2009
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancerPierre Farmer, Hervé Bonnefoi, Pascale Anderle, et al.
Annals of Surgical Oncology|December 24, 2011
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancerManfred Kaufmann, Gunter von Minckwitz, Elefhterios P Mamounas, et al.
The New England Journal of Medicine|October 15, 2011
Breast-cancer adjuvant therapy with zoledronic acidRobert E Coleman, Helen Marshall, David Cameron, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2013
Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trialOtto Metzger-Filho, Marion Procter, Evandro de Azambuja, et al.
Lancet (London, England)|February 21, 2017
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trialDavid Cameron, Martine J Piccart-Gebhart, Richard D Gelber, et al.
Frontiers in Nutrition|February 1, 2021
Analysis of Human Faecal Host Proteins: Responsiveness to 10-Week Dietary Intervention Modifying Dietary Protein Intake in Elderly MalesJessica L Gathercole, Anita J Grosvenor, Erin Lee, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 25, 2015
Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working groupElena Provenzano, Veerle Bossuyt, Giuseppe Viale, et al.
Pageof 49

Showing results (401-410 of 481) with videos related to

Sort By:
Pageof 49
The New England Journal of Medicine|December 29, 2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancerCharles E Geyer, John Forster, Deborah Lindquist, et al.
Nucleic Acids Research|January 12, 2020
Artificial escape from XCI by DNA methylation editing of the CDKL5 geneJulian A N M Halmai, Peter Deng, Casiana E Gonzalez, et al.
Nutrition (Burbank, Los Angeles County, Calif.)|April 30, 2021
Responsiveness of one-carbon metabolites to a high-protein diet in older men: Results from a 10-wk randomized controlled trialNicola A Gillies, Amber M Milan, Pamela H P Chia, et al.
Nature Medicine|January 6, 2009
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancerPierre Farmer, Hervé Bonnefoi, Pascale Anderle, et al.
Annals of Surgical Oncology|December 24, 2011
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancerManfred Kaufmann, Gunter von Minckwitz, Elefhterios P Mamounas, et al.
The New England Journal of Medicine|October 15, 2011
Breast-cancer adjuvant therapy with zoledronic acidRobert E Coleman, Helen Marshall, David Cameron, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2013
Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trialOtto Metzger-Filho, Marion Procter, Evandro de Azambuja, et al.
Lancet (London, England)|February 21, 2017
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trialDavid Cameron, Martine J Piccart-Gebhart, Richard D Gelber, et al.
Frontiers in Nutrition|February 1, 2021
Analysis of Human Faecal Host Proteins: Responsiveness to 10-Week Dietary Intervention Modifying Dietary Protein Intake in Elderly MalesJessica L Gathercole, Anita J Grosvenor, Erin Lee, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 25, 2015
Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working groupElena Provenzano, Veerle Bossuyt, Giuseppe Viale, et al.
Pageof 49